Thymidylate synthase inhibitors for non-small cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 20, Issue 10, 2011, Pages 1343-1356

  Galvani, Elena ^a,b   Peters, Godefridus J ^a   Giovannetti, Elisa ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

NSCLC; Pemetrexed; Pharmacogenetics; Thymidylate synthase

Indexed keywords

AFATINIB; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IFOSFAMIDE; IRINOTECAN; LAPATINIB; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; SORAFENIB; SUNITINIB; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UFT; UNINDEXED DRUG; VINBLASTINE; VINDESINE;

ALOPECIA; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARMACOGENETICS; REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; THYMIDYLATE SYNTHASE;

EID: 80052755036     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.617742     Document Type: Review

References (107)

1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;20:476-87
2. Scagliotti GV, Parikh P, von PJ, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
3. Okamoto I, Yoshioka H,Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 2010;28:5240-6
4. Lehman NL. Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 2002;11:1775-87 (Pubitemid 35469921)
5. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003;14(Suppl 5):v61-118 (Pubitemid 46417464)
6. Qiao X, Tullgren O, Lax I, et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003;41:1-11 (Pubitemid 36765477)
7. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-22
8. Crino L, Weder W, van MJ, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v103-15
9. Marino P, Preatoni A, Cantoni A, et al. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 1995;13:1-12
10. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004;292:470-84 (Pubitemid 38988956)
11. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-57
12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. (Pubitemid 34438899)
13. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926-36 (Pubitemid 46224111)
14. Reck M, von PJ, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
15. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009;6:259-65
16. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
17. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-8
18. Ku GY, Haaland BA, de Lima LG. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer 2011 May 10. [Epub ahead of print]
19. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66
20. Arango BA, Castrellon AB, Santos ES, et al. Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer 2009;10:91-8
21. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995;13:645-51
22. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97 (Pubitemid 41079796)
23. Reck M, Mok T, Wolf J, et al. Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opin Drug Saf 2011;10:147-57
24. Gridelli C, Maione P, Rossi A, et al. New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther 2009;9:115-24
25. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995;64:721-62
26. Rahman L, Voeller D, Rahman M, et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004;5:341-51. (Pubitemid 38482070)
27. Chen M, Rahman L, Voeller D, et al. Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene 2007;26:4817-24 (Pubitemid 47093170)
28. Muggia FM, Peters GJ, Landolph JR. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009;8:992-9
29. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8 (Pubitemid 37328853)
30. Ju J, Pedersen-Lane J, Maley F, et al. Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 1999;96:3769-74 (Pubitemid 29168985)
31. Chu E, Takechi T, Jones KL, et al. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biol 1995;15:179-85 (Pubitemid 24379914)
32. Giovannetti E, Backus HH, Wouters D, et al. Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells. Nucleosides Nucleotides Nucleic Acids 2008;27:740-5 (Pubitemid 351948577)
33. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G1/S-regulatory genes. Mol Cell Biol 1995;15:4215-24
34. Chu E, Voeller D, Koeller DM, et al. Identification of an RNA binding site for human thymidylate synthase. Proc Natl Acad Sci USA 1993;90:517-21. (Pubitemid 23028894)
35. Lin X, Parsels LA, Voeller DM, et al. Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA. Nucleic Acids Res 2000;28:1381-9 (Pubitemid 30142681)
36. Zhang Y, Yang S, Liu M, et al. Interaction between thymidylate synthase and its cognate mRNA in zebrafish embryos. PLoS One 2010;5:e10618
37. Kitchens ME, Forsthoefel AM, Rafique Z, et al. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. J Biol Chem 1999;274:12544-7
38. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-17. (Pubitemid 46332443)
39. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
40. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24
41. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-63.
42. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40
43. Paz-Ares LG, De Marinis F, Dediu M, et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):abstract CRA7510
44. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96 (Pubitemid 44546920)
45. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d] pyrimidinebased antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23 (Pubitemid 27138611)
46. Chen VJ, Bewley JR, Andis SL, et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998;78(Suppl 3):27-34
47. Takimoto CH. New antifolates: pharmacology and clinical applications. Oncologist 1996;1:68-81 (Pubitemid 126669374)
48. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-18 (Pubitemid 41002949)
49. Giovannetti E, Lemos C, Tekle C, et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008;73:1290-300. (Pubitemid 351439211)
50. Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011;104:1594-601
51. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007;25:417-23 (Pubitemid 47222911)
52. Gomez HL, Santillana SL, Vallejos CS, et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006;12:832-8 (Pubitemid 43259865)
53. Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010;28:1534-9.
54. Zucali PA, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 2011;17:2581-90
55. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011; [Epub ahead of print]
56. Sun JM, Han J, Ahn JS, et al. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011; [Epub ahead of print]
57. Higashiyama M, Kodama K, Yokouchi H, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer 2001;34:407-16 (Pubitemid 33041477)
58. Nakagawa T, Tanaka F, Otake Y, et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002;35:165-70 (Pubitemid 34136094)
59. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008;112:2765-73 (Pubitemid 351969222)
60. Edler D, Kressner U, Ragnhammar P, et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000;6:488-92 (Pubitemid 30111468)
61. Novello S, Scagliotti G, Torri V, et al. International tailored chemotherapy adjuvant trial: ITACA trial. J Clin Oncol 2011;29(Suppl):abstract e17514
62. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007;26:153-81 (Pubitemid 46452189)
63. Uemura T, Oguri T, Ozasa H, et al. ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci 2010;101:2404-10
64. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006;9:227-46 (Pubitemid 44750843)
65. Liani E, Rothem L, Bunni MA, et al. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-99 (Pubitemid 36091461)
66. Zhao R, Titus S, Gao F, et al. Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 2000;275:26599-606
67. Pizzorno G, Moroson BA, Cashmore AR, et al. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 1995;55:566-73
68. Stark M, Wichman C, Avivi I, et al. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009;113:4362-9
69. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-65 (Pubitemid 32245569)
70. Zhao R, Zhang S, Hanscom M, et al. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005;11:1294-301 (Pubitemid 40175783)
71. Chattopadhyay S, Zhao R, Krupenko SA, et al. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006;5:438-49
72. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003;66:403-56 (Pubitemid 137640823)
73. Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997;89:1013-18 (Pubitemid 27121295)
74. Zhao R, Gao F, Hanscom M, et al. A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004;10:718-27 (Pubitemid 38180440)
75. Zhao R, Qiu A, Tsai E, et al. The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 2008;74:854-62
76. Gonen N, Bram EE, Assaraf YG. PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells. Biochem Biophys Res Commun 2008;376:787-92
77. Diop-Bove NK, Wu J, Zhao R, et al. Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. Mol Cancer Ther 2009;8:2424-31
78. Ansfield FJ, Kallas GJ, Singson JP. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1983;1:107-10 (Pubitemid 14176798)
79. Keicho N, Saijo N, Shinkai T, et al. Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 1986;16:143-6
80. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57 (Pubitemid 26276346)
81. Tanaka F, Wada H, Fukushima M. UFT and S-1 for treatment of primary lung cancer. Gen Thorac Cardiovasc Surg 2010;58:3-13
82. Surmont V, Aerts JG, Pouw E, et al. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. Lung Cancer 2009;66:333-7
83. Sandler A, Graham C, Baggstrom M, et al. An open-label, multicenter, three-stage, phase ii study of S-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; Epub ahead of print.
84. Okabe T, Okamoto I, Tsukioka S, et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 2008;7:599-606 (Pubitemid 351492458)
85. Okabe T, Okamoto I, Tsukioka S, et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines withMET amplification. Clin Cancer Res 2009;15:907-13
86. Takeda M, Okamoto I, Hirabayashi N, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2011;73:103-9
87. Yamamoto N, Yamanaka T, Ichinose Y, et al. Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. Anticancer Res 2010;30:2985-90
88. Manegold C, Buchholz E, Kloeppel R, et al. Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer. Lung Cancer 2002;36:183-9 (Pubitemid 34296560)
89. Mendiola C, Vaz MA. Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. Clin Transl Oncol 2009;11:554-7
90. Han JY, Hong EK, Lee SY, et al. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol 2005;58:650-4 (Pubitemid 40814029)
91. Ko JC, Tsai MS, Kuo YH, et al. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine. Biochem Pharmacol 2011;81:680-90
92. Kindwall-Keller T, Otterson GA, Young D, et al. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin. Cancer Res 2005;11:1870-6 (Pubitemid 40471852)
93. Giovannetti E, Zucali PA, Peters GJ, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010;9:581-93
94. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003;63:2898-904 (Pubitemid 36667162)
95. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191-7
96. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-45
97. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010;28:614-19.
98. Wynes MW, Dziadziuszko R, Singh S, et al. Thymidylate synthase (TS) gene copy number in NSCLC. J Clin Oncol 2010;28(Suppl):abstract e21063
99. Boni V, Bitarte N, Cristobal I, et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010;9:2265-75
100. Giovannetti E, Erozenci A, Smit J, et al. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 2011; [Epub ahead of print]
101. Li T, Ling YH, Goldman ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007;13:3413-22 (Pubitemid 46944930)
102. Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 2010;9:1647-56
103. Tekle C, Giovannetti E, Sigmond J, et al. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 2008;99:750-9
104. Ceppi P, Rapa I, Lo IM, et al. Expression and pharmacological inhibition of thymidilate synthase and Src kinase in non-small cell lung cancer. Int J Cancer 2011; [Epub ahead of print]
105. Hanauske AR, Lahn M, Musib LC, et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009;20:1565-75
106. Giovannetti E, Honeywell R, Hanauske AR, et al. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets 2010;11:12-28
107. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22(4):333-8